Skip to main content
. 2021 Jan 7;20:6. doi: 10.1186/s12933-020-01175-5

Table 3.

Safety and adverse events

Placebo (N = 22) Empagliflozin (N = 20)
Adverse events 10 5
Serious adverse events 4 6
Hypoglycemic events 2 4
Death 0 0
Adverse event leading to discontinuation of a study drug 0 1
Acute renale failure 0 0
Event consistent with volume depletion 0 3
Thromboembolic event 0 1
Diabetic ketoacidosis 0 0
Urinary tract infection 0 1
Genital infection 0 4
Bone fracture 0 0